Oncopeptides AB (LTS:0RN4) Selling and Marketing Expense : kr128.48 Mil (TTM As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Oncopeptides AB Selling and Marketing Expense?

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. Oncopeptides AB's Selling and Marketing Expense for the three months ended in Sep. 2024 was kr29.83 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Sep. 2024 was kr128.48 Mil.

Oncopeptides AB Selling and Marketing Expense Historical Data

The historical data trend for Oncopeptides AB's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB Selling and Marketing Expense Chart

Oncopeptides AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Selling and Marketing Expense

Get a 7-Day Free Trial

127.41

456.53

698.35

58.10

119.60

Oncopeptides AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Selling and Marketing Expense	Get a 7-Day Free Trial															28.81	34.75	27.72	36.19	29.83

Oncopeptides AB Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr128.48 Mil.

Oncopeptides AB Selling and Marketing Expense Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's Selling and Marketing Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncopeptides AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (LTS:0RN4) » Definitions » Selling and Marketing Expense

Comparable Companies

Traded in Other Exchanges

ONCO:Sweden OND:Germany

Address

Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53

Website

https://www.oncopeptides.com

Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.

Oncopeptides AB Headlines

No Headlines